09/22/2004 • Laboratory diagnostics

Validated test for risk assessment in breast cancer - FEMTELLE uPA/PAI-1

The new FEMTELLE uPA/PAI-1 Test from American Diagnostica allows for improved risk assessment of the course of the disease in node-negative breast-cancer patients. After many years (> 10 years) of clinical studies the value of the test has been confirmed in a population of more than 8000 patients.

FEMTELLE is intended for the quantitative determination of human urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in tumour tissue extracts. The test results are useful to identify patients who are either at high risk (uPA and/or PAI-1 high) or low risk (uPA and PAI-1 low) for disease recurrence after surgery.

uPA and PAI-1 are the first novel tumour biological prognostic factors for which the prognostic impact has been validated at the highest level of evidence and hence all evaluation criteria for transfer into clinical praxis have been fulfilled. The assay is robust and its high reproducibility has been demonstrated in the prospective evaluation of an international quality assurance program. FEMTELLE is registered as a CE marked IVD (in vitro diagnostic medical device).

Whitepaper-Download (121 KB)

This product information
is expired!

Use our search-function for current products ...
gradient arrows

American Diagnostica GmbH

Kaplaneigasse 35
64319 Pfungstadt

Phone: +49 (0) 6157 80 38 17
Fax: +49 (0) 6157 99 08 08